Advertisement
Advertisement
U.S. markets open in 4 hours 24 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kinarus Therapeutics Holding AG (KNRS.SW)

Swiss - Swiss Delayed Price. Currency in CHF
0.01640.0000 (0.00%)
As of 05:30PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0164
Open0.0166
Bid0.0162 x N/A
Ask0.0168 x N/A
Day's Range0.0164 - 0.0168
52 Week Range0.0082 - 0.0366
Volume188,927
Avg. Volume2,716,415
Market Cap17.54M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est107.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for KNRS.SW

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

      KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in preparation Basel, Switzerland, January 17, 2023. Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fib

    • GlobeNewswire

      Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

      Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report new antiviral data of KIN001 against SARS-CoV-2 Omicron BA.2 and BA.5 subvariantsKINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting Basel, Switzerland, 6 December 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical com

    • GlobeNewswire

      Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

      Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 1

    Advertisement
    Advertisement